Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00091247 · ClinicalTrials.gov registry record · NA
Tetracycline in Preventing Skin Rash in Patients Who Are Receiving Drugs Such as Gefitinib and Cetuximab for Cancer
A NA study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- NA
- Development phase
- 130
- Enrollment target
NCT00091247 is a NA study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 130 participants.
The verdict
NCT00091247, a NA study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- NA
- Development phase
- 130 participants
- Enrollment target
Study Summary
RATIONALE: Tetracycline may be effective in preventing skin rash that is caused by treatment with drugs such as gefitinib or cetuximab. PURPOSE: This randomized clinical trial is studying tetracycline to see how well it works compared to placebo in preventing skin rash in patients who are receiving drugs such as gefitinib or cetuximab for cancer.
Interventions
- OTHER placebo
- DRUG tetracycline hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2004-12 |
| Est. Completion | 2009-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00091247
The ClinicalTrials.gov registry entry for NCT00091247 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00091247 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00091247 about?
NCT00091247 is a clinical study titled "Tetracycline in Preventing Skin Rash in Patients Who Are Receiving Drugs Such as Gefitinib and Cetuximab for Cancer". RATIONALE: Tetracycline may be effective in preventing skin rash that is caused by treatment with drugs such as gefitinib or cetuximab. PURPOSE: This randomized clinical trial is studying tetracycline to see how well it works compared to placebo in preventing skin rash in patients who are receiving...
What is the current status of trial NCT00091247?
This trial is currently completed. It is a NA study. The enrollment target is 130 participants. The study started on 2004-12. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00091247?
The interventions under investigation include: placebo (OTHER), tetracycline hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00091247?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.